Indivior Pharmaceuticals, Inc. Common Stock (INDV) News
Latest headlines that mention INDV, newest first · each headline opens the original publisher
- Last price
- $34.72
- Day change
- -0.22%
- Next earnings
- 2026-10-29 BMO
INDV headlines
latest coverageIndivior's relative strength line has bolted to new high ground. The post IBD 50 Stock Indivior Breaks Out Amid Big Fund Ownership Expansion, Strong Profit Prospects appeared first on Investor's Business Daily .
Indivior, a leader in opioid dependence therapies, reported a notable insider sale following a year of exceptional share price gains.
Indivior develops buprenorphine-based treatments for opioid dependence, serving markets in the US, UK, and worldwide.
Indivior develops buprenorphine-based therapies for opioid dependence, serving healthcare providers and treatment centers worldwide.
Medical stock Indivior is in a buy zone after first-quarter earnings. Indivior makes treatments for opioid addiction. The post Medical Stock In Buy Zone After Breakout By Opioid-Addiction Treatment Maker appeared first on Investor's Business Daily .
Indivior develops proprietary treatments for opioid dependence, generating revenue from specialty pharmaceuticals across global markets.
INDV news alerts
Get an alert by email or push when a new headline mentions INDV.
More news
News headlines aggregated from third-party publishers via public RSS feeds and tagged with the tickers they mention. Frenzy Capital does not publish or endorse the content; clicking a headline opens the original publisher in a new tab.